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Abstract 
Background: In the search for valid biomarkers in inflammatory diseases, cytokine serum concentrations are often 
measured by enzyme-linked immunosorbent assay and correlated to disease activity. Interleukin-33 is a relatively 
newly described cytokine, which holds a promising potential as a biomarker for different diseases including atopic 
dermatitis. However, interfering human anti-animal IgG antibodies and heterophilic antibodies might give rise to false 
positive or negative results that often go unnoticed.
Findings: We performed a three-step validation of commercially available and widely used human interleukin-33 
enzyme-linked immunosorbent assay kit with serum samples from eight atopic dermatitis patients and five healthy 
controls. Through addition of unspecific animal IgG (rabbit, mouse, goat and bovine) and unspecific human IgG to the 
assay diluent, we disclosed false positive values in 12 out of 13 samples.
Conclusion: This study show that the present human interleukin-33 enzyme-linked immunosorbent assay kit might 
give rise to a high prevalence of false positive values if not validated. This inaccuracy is easily eliminated with a simple 
set of validation steps.
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Background
Atopic dermatitis (AD) is a chronic inflammatory skin 
disease with high prevalence, substantial morbidity, and 
great effect on quality of life. Treatment is challeng-
ing and depends on previous treatment responses, side 
effects and disease severity (Proudfoot et  al. 2013). For 
these reasons a reliable, consistent biomarker correlating 
with disease activity is needed. Interleukin-33 (IL-33) is a 
newly described cytokine in the context of AD (Schmitz 
et  al. 2005). IL-33 is a nuclear cytokine from the IL-1 
family constitutively expressed in epithelial barrier tis-
sues and lymphoid organs, which plays important roles 
in type-2 innate immunity and atopic disease (Moussion 
et al. 2008). IL-33 functions as an alarmin (alarm signal) 
rapidly released upon cellular damage or stress (Cevik-
bas and Steinhoff 2012). Studies of IL-33 serum con-
centrations in different diseases have been undertaken 
also recently in AD, proposing increased concentrations 
compared to healthy controls (Tamagawa-Mineoka et al. 
2014). We have undertaken a methodological approach 
to the evaluation of IL-33 in serum from AD patients.
Enzyme-linked immunosorbent assay (ELISA) is the 
gold standard when interrogating serum analytes but 
even so the challenge with interfering human anti-ani-
mal IgG antibodies (HAAA) and heterophilic antibodies 
can cause unnoticeable false positive or negative results 
(Willman et  al. 2001; Kricka 1999). Recommendations 
have been made to face interference in immunological 
assays, in particular two-site (sandwich) immunoassays 
(Kragstrup et  al. 2013). Circulating HAAAs can result 
from both iatrogenic and noniatrogenic causes (Kricka 
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1999), while heterophilic arise in healthy individuals as 
natural antibodies (Levinson and Miller 2002).
Several mechanisms of antibody interference are 
assumed (Klee 2000). One is potential bridging of the 
capture and signal antibody that might cause falsely high-
test values. Another is that HAAAs may diminish the 
signal by blocking the analyte binding to capture and/or 
detection antibody producing incorrectly low-test val-
ues. Furthermore, antibodies against the idiotype of the 
original image (anti-idiotypic antibody) and therapeu-
tic antibody that blocks the activity of the reagent cap-
ture antibody cause falsely low measurements and lastly 
anti-anti-idiotypic antibodies, which mimic the reagent 
capture antibody could also cause falsely low measure-
ment. The presence of human anti-animal IgG antibod-
ies against mouse and bovine that through bridging 
gives rise to falsely high results is presumably the biggest 
problems of the above mentioned and reports of extraor-
dinary prevalence of human anti-animal IgG antibodies 
(95 %) in patient sera and the high correlation with false 
positive results (p  <  0.0001) makes validation of both 
commercially bought and in-house ELISA kits meaning-
ful (Andersen et al. 2004). One way of doing this is fol-
lowing a set of validation steps to evaluate and improve a 
sandwich ELISA (Kragstrup et al. 2013).
Results
We validated the present ELISA kit in three steps with 
serum samples from 8 AD patients and 5 healthy con-
trols. We evaluated noise-to-signal ratio with two differ-
ent blocking buffers. However, we did not observe any 
effect of additional blocking, suggesting that the block-
ing by the manufacturer is adequate (data not shown). 
Secondly, we evaluated possible false negative results by 
spiking samples with known concentrations of recom-
binant human IL-33. We did not observe any problems 
with false negative results (data not shown). Finally, we 
evaluated false positive results by adding a mix of unspe-
cific animal IgG (rabbit, mouse, goat and bovine) and 
unspecific human IgG to the assay diluent. This step 
disclosed false positive values in 12 out of 13 samples. 
The serum concentrations before and after preincuba-
tion with IgG mix are shown in Fig. 1. This gave rise to 
an unpredictable but consistent and significant reduc-
tion of the measured values (Wilcoxon matched pairs 
signed rank test: p  =  0.0005). The fold reduction from 
adding IgG mix was median 7.7; IQR 26.8; minimum 1.0; 
maximum 504.5. Additional details are described in the 
“Methods” section.
Discussion
The evaluation of biomarkers often involves the use of 
sandwich ELISA techniques. Undertaking validation 
of any ELISA kit is important prior to main analyses as 
HAAA and heterophilic antibodies are commonly found 
in plasma from both patients and controls ultimately 
leading to interference and false results consequently 
erroneous conclusions. In this study we show that there 
is a high prevalence of incorrectly elevated values occur-
ring from nonspecific HAAAs cross-linking the capture 
and signal antibodies of the IL-33 immunoassay by bind-
ing to isotypic determinants expressed on the Fc portions 
of both antibodies. We also show that this phenomenon 
is easily unveiled and removed with unpretentious meth-
ods of validation.
As this specific IL-33 sandwich ELISA kit was commer-
cial manufactured the element of personal optimization 
is heavily restricted compared to in-house ELISA sys-
tems. Nonetheless validation makes just as much sense 
as with any other kit or setup and the testing of blocking 
agents and falsely positive/negative values is pivotal.
Two different blocking agents was tested compared to 
the protocol that dictated no agent at all. We showed that 
neither PBS with 1  % BSA nor PBS with 5  % skimmed 
milk decreased the noise to signal ratio thus no additional 
blocking was needed. We saw no false negative results in 
either patient or control material, though on the contrary 
the prevalence of false positive results was very high. This 
unspecific interference was eliminated by preincubation 
of samples with a mix of goat, rabbit, mouse, bovine and 
human IgG. As individual testing of each species IgG was 
not done we have no insight to which one might have 
impacted the results the most.
Conclusion
The use of ELISA systems in serological biomarker 
research is both elegant and cost-effective but any kit 
should be subjected to a set of validation steps. This study 
Fig. 1 Identification and removal of false positive results by pre-
incubating samples with a combination of rabbit, mouse, goat, 
bovine, and human immunoglobulins. Note the logarithmic y-axis. P 
patient, C control, IgG immunoglobulin G
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show that the present human IL-33 ELISA kit might give 
rise to a high prevalence of false positive values if not 
validated. This inaccuracy is easily eliminated with a sim-
ple set of validation steps that could be applied to any in-
house or commercially available ELISA kit.
Methods
Samples
Blood samples from eight patients with clinical verified 
AD all suffering from moderate to severe disease (SCO-
RAD 28.0–85.5) with no other registration apart from 
diagnosis were used. Five healthy controls with no his-
tory of either dermal or systemic inflammatory disease 
matched by age and gender were included as reference. 
All blood samples were stabilised with EDTA before frac-
tionation by centrifugation and plasma retrieval.
Reagents and antibodies
The IL-33 ELISA kit used in our analyses was bought of 
BioLegend Inc (GeneID: 90865, Cat. No. 435908, Bio-
Legend, San Diego, USA). It supplied anti-human IL-33 
pre-coated 96-well strip microplates, IL-33 detection 
antibody, lyophilized human IL-33 standard, horserad-
ish peroxidase (HRP) conjugated streptavidin, substrate 
solution, stop solution, assay diluent and wash buffer 
(20x). Rabbit, mouse, goat, and bovine IgG for blocking 
potential anti-animal IgG antibodies in the samples to 
be measured were purchased from Jackson ImmunoRe-
search (catalog numbers 011-000-003, 015-000-003, 
005-000-003 and 001-000-003, West Grove, USA) and 
human immunoglobulin for blocking potential anti-
human immunoglobulin antibodies in the samples were 
purchased from Behring (Beriglobulin, King of Prussia, 
USA). Buffers to block non-specific binding sites in poly-
styrene wells were prepared with PBS pH 7.4 and bovine 
serum albumin (BSA) (catalog number 12659, Calbio-
chem, San Diego, USA) or Skimmed milk 5 % (Part No: 
1.15363.0500, EMD Millipore, Merck, Germany).
Assay diluent
As the assay diluent came fully prepared from the manu-
facturer it was either used pure or mixed with a combina-
tion of 20 μg/ml mouse IgG, 20 μg/ml rabbit IgG, 20 μg/
ml goat IgG, 20  μg/ml bovine IgG and 20  μg/ml heat 
aggregated human IgG. IgG concentrations were selected 
on the basis of the present literature in the field (DeForge 
et al. 2010; Kricka 1999; Kricka et al. 1990; Koshida et al. 
2010; Kragstrup et  al. 2013). All samples and standards 
were left to preincubate in assay diluent or assay dilu-
ent +  IgG mix for 15  min at RT before addition to the 
plate. Samples were diluted 1:1 and 100  μl were added 
and the plate was incubated over night at 4 °C.
Blocking
The need of a blocking agent was questioned as the pre-
sent ELISA kit was pre-coated and the manufactures pro-
tocol does not suggest blocking of the primary antibody 
before application of samples. We chose three different 
settings to evaluate a potential need of this. We tested 
this in wells with blank assay diluent only and 2 h at RT 
with either PBS with 5 % skimmed milk or PBS with 1 % 
BSA or no blocking prior to adding assay diluent.
Wash
Preceding all steps each well was washed four times with 
the supplied wash buffer in a 1:20 dilution with deionized 
water. Before adding substrate solution five washes and 
increased soaking time was carried out as recommended 
by the manufacturer.
Capture and detection antibodies and streptavidin‑HRP
All reagents were supplied in the kit and were used 
according to the manufacturers protocol.
Measurement of optical density
The optical density (OD) of each well was measured 
within 10 min from adding stop solution. The microplate 
reader was set to 450  nm and wavelength correction at 
570.
Calculations and graphs
As data did not follow a Gaussian distribution a non-
parametric Mann–Whitney test was used to evaluate 
the impact of IgG mix. Mean OD values from doublets 
were calculated and the mean blank value was sub-
tracted. Adding rh IL-33 to samples from three different 
AD patients tested spike recovery. Recovery was calcu-
lated as OD of the spiked sample subtracted the unspiked 
sample, divided by the expected value and multiplied by 
100 %: Recovery = (ODspiked − ODunspiked) ⁄ Expected 
spiked  ×  100  %. The standard curve was fitted with a 
5-parameter logistic nonlinear regression model using 
the MasterPlex ReaderFit version 2.0.0.68 (MiraiBio 
Group of Hitachi Solutions America, Ltd, USA) and cut-
off value was set at 1.95 pg/ml. Measurements below the 
cut-off values were assigned the cut-off value. Statistics 
were done in STATA version 12.0 (StataCorp, College 
Station, Texas, USA). Graphs were made in GraphPad 
Prism version 6 (GraphPad software, San Diego, USA). A 
p value of less than 0.05 was considered significant.
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